Feb 20, 2020 - The agency expects to make a decision by Aug. 21, 2020.
Jan 28, 2020 - The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
Jan 27, 2020 - BMO Capital Markets issues rating change for BMRN
Jan 20, 2020 - These stocks could thump the broader markets this year.
Jan 16, 2020 - If approved, Valrox could become the most expensive drug in the world.
Jan 14, 2020 - BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
Dec 24, 2019 - BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Dec 05, 2019 - Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Nov 28, 2019 - REGN vs. BMRN: Which Stock Is the Better Value Option?
Nov 27, 2019 - Barclays issues rating change for BMRN